

Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars

- Xbrane Biopharma AB (publ.) ("Xbrane" or the "Company") is quickly advancing its portfolio of biosimilars with targeted launch of leading product Xlucane (Lucentis® biosimilar) in 2022.
- To better equip the company for commercialization of its biosimilars Xbrane strengthens its management team with Regulatory Affairs, Manufacturing and Supply Chain and Business Development competences.
- Maria Edebrink, Head of Regulatory Affairs, with over 28 years of experience from AstraZeneca, Galderma and Medivir, will form part of the management team as of February 21st 2020.
- Anders Wallström, Head of Manufacturing and Supply Chain, with over 19 years of commercial supply chain experience from SOBI and Biovitrum, will form part of the management team as of February 21st 2020.
- Xiaoli Hu, recently recruited as Head of Business Development, with experience from Affibody and HealthCap, will join Xbrane and form part of the management team as of May 1st 2020.
- Paolo Sarmientos, Head of long-acting injectables and CEO of Xbrane's subsidiary Primm Pharma, will, provided Xbrane's strategic focus on biosimilars, no longer form part of the management team as of February 21st 2020.

Maria Edebrink, Head of Regulatory Affairs, brings over 28 years of experience to the management team

Maria Edebrink joined Xbrane during 2019 as Head of Regulatory Affairs and has since then led the preparatory work for Marketing Authorization Application for Xlucane in Europe and the US. Maria has altogether over 28 years of experience from Pharmaceutical Development and Regulatory Affairs from AstraZeneca, Galderma and Medivir. Maria has been instrumental in the development, approval and maintenance of regulatory approvals of multiple pharmaceutical and medical device products, amongst them Brilinta®/Brilique® at AstraZeneca currently generating annual sales of USD 1.5 billion. Maria holds a M. Sc. in Chemistry from Stockholm University. Maria will form part of Xbrane's management team as of February 21st 2020.

Anders Wallström, Head of Manufacturing and Supply Chain, brings over 19 years of experience to the management team

Anders Wallström joined Xbrane during 2019 as Head of Manufacturing and Supply Chain and has

since worked with the establishment of the commercial supply chain for Xlucane. Anders has over 19 years of experience from process development, manufacturing and validation of biological products at SOBI and Biovitrum. In Anders last role at SOBI he was end-to-end supply chain director for specialty care products including Kineret® and Orfadin®. Anders holds a M.Sc. in Biotechnology from Royal Institute of Technology in Stockholm. Anders will form part of Xbrane's management team as of February 21st 2020.

Xiaoli Hu, Head of Business Development, brings strong deal-making capabilities to Xbrane

Xiaoli Hu will join Xbrane as Head of Business Development on May 1st 2020 and will then be part of the management team. She will be primarily responsible for the establishment of new partnerships for commercialization of Xbrane's pre-clinical biosimilars. Xiaoli has gained first-hand experience in business development from the pharmaceutical industry, most recently as Business Development Director at Affibody, where she led the work towards the USD 650 million commercial partnership deal with Alexion and the co-development deal with GE Healthcare. Prior to that, Xiaoli spent nearly four years at HealthCap, a leading Nordic Healthcare investor. During her tenure at HealthCap, she has joined and completed investment transactions across various geographies and stages of development. Xiaoli received her Medical Doctor degree from Shanghai Jiaotong University, and holds a PhD in Medical Science from Karolinska Institute. Xiaoli will form part of Xbrane's management team as of May 1st 2020.

Paolo Sarmientos steps out of the management team provided Xbrane's focus on biosimilars

Xbrane announced in September 2018 its strategic focus on biosimilars. As a consequence of this Paolo Sarmientos, Head of long-acting injectables and CEO of Xbrane's subsidiary Primm Pharma, will as of February 21st, 2020, no longer form part of Xbrane's management team.

Contacts

Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.

Press Release
21 February 2020 15:00:00 CET



This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-02-21 15:00 CET.

Attachments

[Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars](#)